IEX — IDEX Corporation

IDEX Corporation Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Organic Revenue Growth: 1% for Q4 2025, with adjusted EBITDA margin expanding by 40 basis points year-over-year.
• Adjusted EPS: Exceeded guidance, with Q4 adjusted EPS higher than expected.
• Orders Growth: Overall orders grew 16% organically in Q4; HST segment orders grew 34% organically.
• Free Cash Flow: $617 million for the full year, representing a 2% increase year-over-year, with a conversion rate of 103% of adjusted net income.
• Share Repurchases: $73 million in Q4, totaling nearly $250 million for the year.

2. Strategic Updates and Business Highlights

• Leadership Change: Sean Gillen joined as CFO, bringing experience in driving profitable growth and operational efficiencies.
• 8020 Playbook: Continued emphasis on the 8020 strategy to enhance operational efficiencies and drive growth across business units.
• HST Segment Performance: Strong growth driven by demand in data centers, semiconductors, and life sciences. Notable organic orders growth of 34% in Q4.
• Acquisition: Successful integration of Microlam, enhancing capabilities in optics and materials processing.
• Market Focus: Targeted growth in high-demand sectors such as AI, data centers, and life sciences.

3. Forward Guidance and Outlook

• 2026 Outlook: Expected organic growth of 1% to 2%, with HST projected to achieve mid-single-digit growth, while FMT and FSDP are anticipated to remain flat or slightly down.
• Adjusted EBITDA Margin: Forecasted to be in the range of 26% to 27% for 2026.
• Adjusted EPS Guidance: Projected between $8.15 and $8.35, indicating low to mid-single-digit growth year-over-year.
• Seasonal Trends: Anticipated typical Q1 softness due to seasonal factors, with a rebound expected in Q2.

4. Bad News, Challenges, or Points of Concern

• Market Softness: Continued weakness in the chemical, energy, and agriculture sectors, particularly impacting FMT.
• Demand Uncertainty: Despite a positive PMI reading, IDEX has not yet observed a significant inflection in demand, particularly in industrial and auto markets.
• Volume Declines: Flat volumes in HST and declines in FMT and FSDP, raising concerns about sustaining growth momentum.
• Geopolitical Risks: Ongoing uncertainties related to global economic conditions and policy headwinds could impact future performance.

5. Notable Q&A Insights

• Order Dynamics: Eric Ashleman noted that while there was strong order growth in Q4, it is essential to differentiate between year-end budget flushes and sustained demand. January showed continued strength in orders.
• Pricing Power: Sean Gillen indicated that pricing contributed approximately 3% to revenue in 2025, with expectations for a slight decrease in 2026.
• M&A Strategy: Focus on bolt-on acquisitions and integration of recent purchases, with ongoing evaluation of portfolio optimization.
• Life Sciences Outlook: Stable growth expected, though there are concerns regarding academic research funding and its impact on business performance.

This summary encapsulates the key takeaways from IDEX's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, guidance, and challenges faced by the company.